Facebook Twitter LinkedIn Instagram Email Printer Google Plus

Howard Lapsley

Partner, Health & Life Sciences, Oliver Wyman

Fourteen percent of physicians offer virtual visits. But a new CMS rule may make telehealth more commonplace.

Partner, Health & Life Sciences, Oliver Wyman
Partner, Health & Life Sciences, Oliver Wyman
Partner, Health & Life Sciences, Oliver Wyman
Partner, Health & Life Sciences, Oliver Wyman
Partner, Health & Life Sciences, Oliver Wyman
Partner, Health & Life Sciences, Oliver Wyman

When it comes it health benefits, paying more doesn't always get you more. But, consumers will open up their wallets for better value.

Partner, Health & Life Sciences, Oliver Wyman

From Walmart to Amazon to 23andMe, these 11 market scenarios paint a picture of what disruption looks like, both in and out of healthcare.

Partner, Health & Life Sciences, Oliver Wyman
Partner, Health & Life Sciences, Oliver Wyman
Chief Strategy Officer, BCBS of Massachusetts
Principal, Health & Life Sciences, Oliver Wyman

Digital distribution industry leaders face a tipping point. Here's how to stay ahead of healthcare’s ongoing disruption.

Chief Product Officer and Co-Founder, Maxwell Health
Partner, Health & Life Sciences, Oliver Wyman

Tomorrow’s healthcare consumer still wants a personalized experience – like that of Apple and Netflix. Here’s how the industry can bridge that gap.

Partner, Health & Life Sciences, Oliver Wyman
Chief Client and Strategy Officer, Lippincott

Insights in your inbox

Subscribe

In the face of today’s market turmoil and revenue insecurity, ancillary products offer a stable, growing profit pool for health plans.

Partner, Health & Life Sciences, Oliver Wyman
Partner, Health & Life Sciences, Oliver Wyman

New political climate positions private exchanges for take-off. Learn why.

Partner, Health & Life Sciences, Oliver Wyman

What does the future hold for brokers? Fast track to dustbin of history or cemented place in new marketplace?

Partner, Health & Life Sciences, Oliver Wyman
Partner, Health & Life Sciences, Oliver Wyman

Private exchanges are here to stay, say Oliver Wyman’s Chris Bernene and Howard Lapsley. Five reasons why payers should double down on private exchange strategy.

Partner, Health & Life Sciences, Oliver Wyman
Partner, Health & Life Sciences, Oliver Wyman

With their strategic control of data and money flow, payers have an opportunity to be the connective tissue for the new healthcare ecosystem.

Partner, Health & Life Sciences, Oliver Wyman

Insights in your inbox

Subscribe